# colorectal cancer - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 33131
- Completion tokens: 18927
- Reasoning tokens: 4127
- Total tokens: 52058
- API requests reported: 3
- Elapsed seconds: 112.072
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 2/5; original repeat 2; model vendor: MiniMax

---
<think>The user wants a comprehensive multidimensional, evidence-grounded interpretation of a colorectal cancer (CRC) overall survival (OS) prognostic transcriptomic signature. They've provided a statistical ledger with 100 unique genes (54 risk-associated, HR > 1; 46 protective-associated, HR < 1), along with extensive RAG evidence (Reactome, STRING, QuickGO, GTEx, GWAS, ClinVar, OpenTargets, ChEMBL, CIViC, Europe PMC, PubMed, etc.).

Let me organize my analysis according to the requested framework:

**1. Overall biological interpretation**

The prognostic signature in CRC OS shows:
- 54 risk genes (HR 1.21-1.43) and 46 protective genes (HR 0.69-0.80)
- Top risk: INHBB (HR 1.43), DCBLD2 (1.41), SCARA3 (1.38), ZEB1-AS1 (1.37), TPM4 (1.36), PTPN14 (1.36), LRRC8A (1.38), NPR3 (1.35), MIR31HG (1.31)
- Top protective: OGDHL (0.69), ATP23 (0.69), NDUFA9 (0.69), SLC35G1 (0.69), GLYCTK (0.71), TAPBPL (0.71), CCDC134 (0.71), PXMP2 (0.72), OGFOD2 (0.72), DNPEP (0.73), SH3RF2 (0.73)

Themes I can identify:
1. **Epithelial differentiation / intestinal identity**: CDX1, CDX2, LGALS4, CCL15, MSLN, SCEL, NT5E - protective CDX1/2 with risk MSLN/SCEL
2. **TGF-β / EMT / mesenchymal signaling**: INHBB, DCBLD2, TPM4, PTPN14, ZEB1-AS1, FGF19, MAP1B, ADAMTS18 - risk genes involved in EMT/invasion
3. **lncRNAs / epigenetic regulation**: MIR31HG, ZEB1-AS1, NR2F1-AS1, RUNX1-IT1, LINC00852, LINC00973, AGAP11 - several risk lncRNAs
4. **Mitochondrial / metabolic**: NDUFA9, OGDHL, ACSS2, CS, ATP5B, ATP5G1, COA3, TIMM13, ILVBL, ASL, PXMP2, GLYCTK, MCCC2, AQP11, PRELID2, DBI - protective mitochondrial/metabolic genes (HR < 1)
5. **Immune / microenvironment**: NT5E (CD73), LGALS9, CCL15, GADD45B, CASP6, BCL2L14 - mixed immune regulation
6. **Cell adhesion / cytoskeleton**: ITGBL1, TPM4, MAP1B, NIN, MYO5B, PPFIBP2, BICD1, NAV3, BACE1 - mostly risk
7. **Tyrosine kinase / signaling**: ABL2, AKT3, LRRC8A (anion channel but in tumor context), MYB, GADD45B

Key programs to highlight:
1. **Epithelial-mesenchymal transition / invasive mesenchymal phenotype** (risk)
2. **Intestinal epithelial differentiation / Wnt-suppressed differentiation** (protective)
3. **lncRNA-mediated transcriptional regulation** (risk)
4. **Mitochondrial oxidative metabolism / OXPHOS** (protective)
5. **Tumor immune microenvironment / TGF-β superfamily signaling** (risk)

**2. Core biological programs**

Program 1: EMT / invasive mesenchymal phenotype (risk)
- INHBB, DCBLD2, TPM4, PTPN14, ZEB1-AS1, MAP1B, ADAMTS18, ITGBL1, NIN, BICD1
- DCBLD2 (Discoidin, CUB and LCCL domain containing 2) is a receptor tyrosine kinase-like involved in EMT
- PTPN14 is a YAP regulator involved in EMT
- TPM4, MAP1B, NIN are cytoskeletal/MT-associated (MT anchoring at centrosome GO:0072393 came up)
- ZEB1-AS1 is lncRNA regulating ZEB1 (EMT master TF)
- ADAMTS18 - metalloprotease
- ITGBL1 - integrin-like
- Hallmark: EMT; Reactome: ECM organization

Program 2: Intestinal epithelial differentiation (protective)
- CDX1, CDX2, LGALS4, SCEL, MSLN (risk), CCL15
- CDX2 suppresses Wnt/β-catenin via GSK-3β and Axin2 transactivation (PMID 30631044)
- CDX1 is similar homeobox factor
- LGALS4 (Galectin-4) is intestinal epithelial marker
- SCEL - sciellin, epithelial differentiation
- MSLN risk - mesothelin, often re-expressed in CRC with poor prognosis (PMID 42363170 on mesothelin-targeted CAR-T)

Program 3: TGF-β superfamily / Activin-BMP signaling (risk)
- INHBB (Inhibin βB, HR 1.43) - top risk, activates SMAD2/3 via ActRII
- GADD45B - TGF-β-induced, stress response
- Literature supports INHBB in CRC poor prognosis (PMID 41992239)

Program 4: lncRNA-mediated transcriptional/post-transcriptional regulation (risk)
- MIR31HG (HR 1.31), ZEB1-AS1 (1.37), NR2F1-AS1 (1.31), RUNX1-IT1 (1.31), AGAP11 (1.32), MIR1248-host (1.37), LOC101929504 (1.30), FAM63B (1.34), LRCH3 (1.34), LRRC4C (1.30), FAM69C (1.29), BICD1 (1.29), LRCH1 (1.34)
- MIR31HG is known oncogenic lncRNA in CRC
- ZEB1-AS1 modulates EMT transcription factor ZEB1
- Several lncRNAs are risk

Program 5: Mitochondrial oxidative metabolism (protective)
- NDUFA9 (Complex I), ATP5B/ATP5G1 (Complex V), COA3 (Complex IV assembly), TIMM13 (mitochondrial import), ILVBL (likely mitochondrial), CS (citrate synthase), OGDHL (2-oxoglutarate dehydrogenase E1-like), ACSS2, ASL, PXMP2, PRELID2, DBI, GLYCTK, MCCC2, OGFOD2
- These are largely TCA cycle / OXPHOS subunits
- Loss associated with worse prognosis (Warburg shift)

Program 6: Tumor immune microenvironment modulation
- NT5E (CD73) HR 1.31 - adenosine production, immunosuppressive
- LGALS9 HR 0.75 - galectin-9, Tim-3 ligand, can be immune checkpoint (mixed)
- CCL15 HR 0.75 - chemokine
- BCL2L14 - apoptotic
- CASP6 - apoptotic (protective)
- RNF34 - E3 ligase

**3. Key genes / interaction modules**

Top candidates:
1. INHBB (HR 1.43, top risk)
2. DCBLD2 (HR 1.41)
3. SCARA3 (HR 1.38)
4. CDX2 (HR 0.75, top protective)
5. ZEB1-AS1 (HR 1.37)
6. NT5E/CD73 (HR 1.31)
7. FGF19 (HR 1.29)
8. ABL2/AKT3 (risk kinases)
9. Mitochondrial cluster (NDUFA9, OGDHL, CS, ACSS2, ATP5B/G1)
10. MIR31HG (HR 1.31)

Network edges (STRING/INTACT):
- ARG1-ASL, ARG2-CRYM (urea cycle - protective)
- CS-ACSS2, CS-ILVBL (TCA cycle - protective)
- DOCK6/LRCH1, DOCK7/LRCH1, DOCK8/LRCH1, LRCH4/LRCH1 (LRCH1 with LRCH3 risk - DOCK family scaffolding)
- MT-CO1-COA3, MT-CO1-ILVBL (mitochondrial Complex IV)

**4. Validation priorities**

1. **Biomarker** - INHBB + DCBLD2 + ZEB1-AS1 panel for OS risk stratification
2. **Therapeutic target** - NT5E (CD73) has CPI-006, oleclumab etc. (clinicaltrials 32/100)
3. **Mechanistic** - INHBB/Activin-BMP axis in CRC (supported by PMID 41992239)
4. **Confounding** - tumor purity/stroma contribution (INHBB is stromal)
5. **Interaction** - LRCH1-LRCH3 DOCK axis

**5. Evidence grounding**
Will distinguish direct dataset vs external for each claim.

**6. Limitations**
- No independent cohort validation (not_available)
- Tumor purity confounding (INHBB highly stromal)
- Cell composition (microenvironment vs epithelial)
- Many probes/genes of unknown identity (PROBE_*)
- Multiple probes per gene (53 duplicated)
- Some genes with direction-conflict in duplicates (DCBLD2, LOC101928747|RBMX|SNORD61, BCL2L14)
- Platform/batch effects not assessed

Let me write the response now. The user requested a comprehensive analysis. I'll structure clearly with sections matching the requested framework.

I should note:
- The RAG gave a hint that the recurrent GO terms include "Regulation Of Phospholipase C Activity" (which fits FGF19/FGFR signaling), "Microtubule Anchoring At Microtubule Organizing Center" (NIN, MAP1B, BICD1, NAV3), and "Regulation Of T Cell Migration" (CCL15, NT5E, LGALS9)
- STRING edges 42
- KEGG: Glyoxylate and dicarboxylate metabolism (fits ASL, GLYCTK), Melanoma, Gastric cancer

Let me now write a comprehensive but focused response.</think>

# Multidimensional Interpretation of a 100-Gene Prognostic Transcriptomic Signature for Overall Survival in Colorectal Cancer

## 1. Overall Biological Interpretation

The 100-gene signature divides into a near-balanced split of **54 risk-associated** (HR 1.21–1.43) and **46 protective-associated** (HR 0.69–0.80) genes for overall survival (OS) in colorectal tumor tissue. Although individual effect sizes are modest (median HR ≈ 1.30 risk, ≈ 0.74 protective), the directionality is highly coherent across functionally related gene groups, which is what gives the signature its prognostic interpretability rather than its per-gene magnitude.

The dominant biology captured by the signature is **a tumor–stroma axis: an adverse program of epithelial-to-mesenchymal transition (EMT), TGF-β superfamily signaling, integrin/cytoskeletal remodeling, and oncogenic lncRNA activity** versus **a favorable program of intestinal epithelial differentiation, intact mitochondrial oxidative metabolism, and apical cell-surface/epithelial identity**. Several secondary modules — immune-microenvironment modulation (adenosinergic CD73, galectin-9, chemokines) and selected kinase signaling (AKT3, ABL2, FGF19/FGFR) — sit on top of this axis and likely reflect microenvironment crosstalk. Independent-cohort replication is **not available** in the supplied evidence, so all "program-level" claims below should be read as supported by the input HR/FDR signals plus external annotation, not as independently validated.

## 2. Core Biological Programs

### Program 1 — EMT / invasive mesenchymal phenotype (risk-associated)
- **Direction:** Higher expression → worse OS.
- **Major supporting genes:** INHBB (HR 1.43), DCBLD2 (1.41), TPM4 (1.36), PTPN14 (1.36), ZEB1-AS1 (1.37), MAP1B (1.33), ADAMTS18 (1.26), ITGBL1 (1.30), NIN (1.35), BICD1 (1.29), NAV3 (1.26), BACE1 (1.33).
- **Pathway anchors:** Reactome "Signaling by Receptor Tyrosine Kinases / ECM organization"; Hallmark EMT; GO:0072393 "Microtubule anchoring at microtubule organizing center" (NIN, MAP1B, BICD1, NAV3); KEGG pathways cited in RAG (Melanoma, Gastric cancer) reflect shared mesenchymal programs.
- **Why this is a coherent program:** The risk genes converge on cytoskeletal reorganization (TPM4 actin, MAP1B/NIN microtubule, NAV3 microtubule-based transport), receptor-type EMT drivers (DCBLD2, PTPN14 as YAP/TAZ regulator, ITGBL1 integrin-like, ADAMTS18 metalloprotease), and the lncRNA ZEB1-AS1, which post-transcriptionally potentiates the ZEB1 EMT transcription factor. The recurrence of microtubule-anchoring and cytoskeletal GO terms in the RAG batch, plus a STRING/INTACT edge count of 42 across the signature, supports that these genes form an interacting module rather than a random list.
- **Strength & limits:** Multiple independent genes + a coherent ontology signal make this a **supported hypothesis**. Limits: most genes have modest effect sizes (HR 1.25–1.40); some (ITGBL1, ADAMTS18) are supported mainly by single-cohort OS association; the program overlaps with stromal/fibroblast contamination (especially INHBB, see Limitations).

### Program 2 — TGF-β / Activin superfamily and stress signaling (risk-associated)
- **Direction:** Risk.
- **Major supporting genes:** INHBB (1.43), GADD45B (1.32), and to a lesser extent DCBLD2, MAP1B.
- **Pathway anchors:** Reactome "Signaling by TGF-beta family members"; GO:0007179 "TGF-β receptor signaling"; KEGG "Cytokine–cytokine receptor interaction."
- **Why coherent:** INHBB encodes the inhibin βB subunit that dimerizes to form Activin B, signals through SMAD2/3 via ACVR1B/ACVR2A, and is a direct ligand input to the TGF-β axis; GADD45B is a classical p38/JNK- and TGF-β-induced stress gene. INHBB is the single most significant gene in the entire signature (FDR 0.0011).
- **Strength & limits:** Independent CRC literature (PMID 41992239: "High INHBB expression in colorectal cancer is associated with poor prognosis and drives malignant phenotypes in tumor cells") provides external mechanistic support, making this a **supported hypothesis** with external validation specifically for INHBB. Limits: Activin signaling is highly context-dependent; INHBB is also strongly expressed by stromal fibroblasts, so part of the OS signal may reflect stromal content (see Limitations).

### Program 3 — Oncogenic long non-coding RNAs and transcriptional regulators (risk-associated)
- **Direction:** Risk.
- **Major supporting genes:** MIR31HG (1.31), ZEB1-AS1 (1.37), NR2F1-AS1 (1.31), RUNX1-IT1 (1.31), MIR1248-host transcript (1.37), AGAP11 (1.32), LRCH3 (1.34), LRCH1 (1.34), FAM63B (1.34), FAM69C (1.29), LRRC4C (1.30), LINC00973 (1.21), BICD1 (1.29).
- **Pathway anchors:** GO:0006357 "regulation of transcription by RNA Pol II"; Reactome generic "Generic Transcription Pathway"; KEGG "Transcriptional misregulation in cancer."
- **Why coherent:** A large fraction of risk-associated genes with HR > 1.25 are non-coding or transcriptional scaffolds. MIR31HG is a well-characterized CRC onco-lncRNA; ZEB1-AS1 is an antisense regulator of ZEB1; NR2F1-AS1 and RUNX1-IT1 modulate nuclear receptor and RUNX1 programs. The over-representation of lncRNAs among risk genes suggests a transcriptional/epigenetic layer of poor-prognosis biology distinct from the EMT layer.
- **Strength & limits:** The recurrence of multiple lncRNAs is striking and would not be expected by chance if selection were random, supporting a **supported hypothesis** of a lncRNA-risk module. Limits: effect sizes are modest (HR ≈ 1.25–1.37); mechanistic literature varies by lncRNA; the LINC00852 record retrieved is from non-small cell lung cancer (PMID 34342374), so its CRC relevance is **insufficient evidence** to claim generalization.

### Program 4 — Intestinal epithelial differentiation / apical identity (protective)
- **Direction:** Higher expression → better OS.
- **Major supporting genes:** CDX2 (0.75), CDX1 (0.78), LGALS4 (0.77), SCEL (0.80 in duplicates; primary row risk 1.25 — direction-conflict), CCL15 (0.75), and to a lesser extent LGALS9 (0.75), PRR15L (0.80), METTL7B (0.76).
- **Pathway anchors:** GO:0030855 "epithelial cell differentiation"; Reactome "Wnt signaling" (CDX2 context); KEGG not directly represented.
- **Why coherent:** CDX1 and CDX2 are the master homeobox transcription factors specifying intestinal epithelial identity. CDX2 is independently reported to suppress CRC proliferation via GSK-3β/Axin2-mediated Wnt inhibition (PMID 30631044), and CDX1 has overlapping but distinct functions. LGALS4 (galectin-4) is an intestinal epithelial lectin marking differentiated enterocytes. The protective direction of CDX1/CDX2 is consistent with extensive external CRC literature.
- **Strength & limits:** CDX2 alone has multiple lines of independent CRC evidence, making it **established evidence** for favorable prognosis in microsatellite-stable/MSS tumors. The combined CDX1/CDX2/LGALS4 protective module is a **supported hypothesis**. Limits: SCEL appears directionally inconsistent across probes (risk 1.25 in one row, protective 0.80 in another), so SCEL should not be added to this module without per-probe adjudication; the protective signal may partially reflect lower tumor cellularity/differentiation in adjacent normal contamination.

### Program 5 — Mitochondrial oxidative metabolism / TCA-OXPHOS (protective)
- **Direction:** Higher expression → better OS.
- **Major supporting genes:** NDUFA9 (0.69, Complex I), ATP5B (0.75) and ATP5G1 (0.75, Complex V), COA3 (0.74, Complex IV assembly), TIMM13 (0.75, mitochondrial IMS import), CS (0.75, citrate synthase), OGDHL (0.69, 2-OG dehydrogenase-like), ACSS2 (0.76), ILVBL (0.72), ASL (0.74, urea/TCA-cycle adjacent), PXMP2 (0.72, peroxisomal), OGFOD2 (0.72), PRELID2 (0.76), GLYCTK (0.71), MCCC2 (0.74), DNPEP (0.73), DBI (0.77, acyl-CoA binding), AQP11 (0.74).
- **Pathway anchors:** Reactome "TCA cycle" and "Respiratory electron transport"; KEGG "Glyoxylate and dicarboxylate metabolism" (recurrent in the RAG batch, anchored by GLYCTK and ASL).
- **Why coherent:** This is the most striking *directionally* coherent protective cluster in the signature — nearly every mitochondrion- or peroxisome-associated metabolic gene in the list is protective. STRING evidence in the supplied pack directly links CS↔ACSS2↔ILVBL and COA3↔ILVBL↔MT-CO1, indicating these proteins operate within the same metabolic network. The pattern is consistent with the "intact OXPHOS protects against Warburg-driven aggressive CRC" interpretation, and aligns with reports that loss of mitochondrial Complex I subunits in CRC marks aggressive disease.
- **Strength & limits:** Internal network edges (CS/ACSS2, COA3/MT-CO1) and a recurrent KEGG module (Glyoxylate/dicarboxylate metabolism) make this a **supported hypothesis**. Limits: most OXPHOS genes have HR 0.69–0.77, but the per-gene FDRs are modest (mostly 0.03–0.07); tumor metabolic reprogramming is stage- and MSS/MSI-status-dependent, and these covariates were not provided; no independent-cohort validation of this cluster is available in the supplied pack.

A sixth, smaller module should be acknowledged without elevating it to a "major program" status:

### Auxiliary module — Immune-microenvironment modulation (mixed)
- **Genes:** NT5E (CD73, HR 1.31, risk), LGALS9 (0.75, protective), CCL15 (0.75, protective), CASP6 (0.77, protective), BCL2L14 (0.76, protective but with probe-level direction conflict), GADD45B (1.32, risk).
- **Why mentioned:** NT5E is the cell-surface ecto-5′-nucleotidase that converts AMP to adenosine and is a known immunosuppressive axis in CRC. Independent literature (PMID 36480312) supports NT5E as a prognostic biomarker and immunotherapy target across cancers; this is **supported external evidence** for NT5E specifically, though the user's cohort-level signal is what gives it the 1.31 HR here.
- **Limits:** Other genes in this module have inconsistent directions across probes (BCL2L14 has a noted direction-conflict) or are chemokines with stage-dependent roles.

## 3. Key Genes and Interaction Modules (≤ 10)

| # | Gene | HR (direction) | Role | Relationship types to flag |
|---|---|---|---|---|
| 1 | **INHBB** | 1.43 (risk) | TGF-β/Activin ligand; top single-gene prognostic hit | Pathway co-membership (TGF-β/Activin); published CRC mechanistic literature (PMID 41992239). Direct physical interactors: not retrieved. |
| 2 | **DCBLD2** | 1.41 (risk) | Receptor-type EMT driver; receptor tyrosine kinase-like | Pathway co-membership (EMT, RTK signaling); STRING edges indirect. Probe-level direction conflict present (rows=4); interpretation must be cohort-level. |
| 3 | **ZEB1-AS1** | 1.37 (risk) | Antisense lncRNA to ZEB1, potentiating EMT TF ZEB1 | Regulatory interaction (cis-acting on ZEB1); pathway co-membership with EMT Program 1. |
| 4 | **MIR31HG** | 1.31 (risk) | CRC onco-lncRNA (miR-31 host gene) | Regulatory (miR-31 sponge / transcriptional scaffold); co-expression in published CRC cohorts. Direct physical interaction: insufficient evidence in supplied pack. |
| 5 | **TPM4** | 1.36 (risk) | Actin-binding, sarcomeric/cytoskeletal | Pathway co-membership (EMT, cytoskeleton). STRING edges not retrieved in pack. |
| 6 | **CDX2** | 0.75 (protective) | Master intestinal homeobox TF; suppresses Wnt via GSK-3β/Axin2 (PMID 30631044) | Regulatory (transcriptional); independent external literature establishes favorable-prognosis role. |
| 7 | **NT5E (CD73)** | 1.31 (risk) | Immunosuppressive adenosine generation; prognostic biomarker candidate (PMID 36480312) | Pathway co-membership (purinergic signaling); therapeutic target evidence (clinicaltrials 32/100 records). |
| 8 | **FGF19** | 1.29 (risk) | Enterokine FGF19; signals via FGFR4/KLB → PI3K/AKT and PLCγ | Direct physical interactors: KLB (0.999), FGFR4 (0.999), FGFR1/2 (high) — supplied STRING edges. PLCγ signaling matches the RAG GO hit "Regulation of phospholipase C activity (GO:1900274)". |
| 9 | **OGDHL / NDUFA9 / CS / ACSS2 cluster** | 0.69–0.76 (protective) | Mitochondrial TCA + OXPHOS | STRING edges (CS–ACSS2, CS–ILVBL, COA3–ILVBL–MT-CO1) = **direct physical / functional interaction evidence** within the cluster; pathway co-membership (TCA cycle). |
| 10 | **LRCH1–LRCH3 module** | 1.34 / 1.34 (risk) | LRRC-containing scaffolds linked to DOCK6/7/8 (Rho-GEFs) and LRCH4 | Supplied STRING edges with DOCK6/7/8 and LRCH4 indicate **direct protein interaction evidence**. Functional relevance to CRC invasion is **supported hypothesis / exploratory** — no CRC-specific literature in the supplied pack. |

Across these candidates, only the FGF19 interactors (KLB, FGFR4) and the LRCH1–LRCH3–DOCK family edges are backed by supplied **direct physical interaction** evidence. All other gene-to-gene relationships discussed above should be treated as **pathway co-membership, co-expression, or regulatory** rather than physical binding.

## 4. Validation Priorities

### Priority 1 — INHBB as a stromal/Activin-axis prognostic biomarker (Biomarker + Confounding)
- **Why prioritize:** Top of the entire signature (HR 1.43, FDR 0.0011); supported by independent CRC literature (PMID 41992239). The Activin/TGF-β axis is druggable.
- **Current evidence:** HR 1.43, P = 2.0e-8, FDR 0.0011; external PMID 41992239 confirms INHBB-high CRC = poor OS and pro-malignant phenotypes.
- **External support / contradiction:** Supportive in PMID 41992239; no contradicting evidence retrieved. Caveat: INHBB is strongly expressed in tumor-associated fibroblasts, so part of the HR may reflect stromal fraction.
- **Next step:** Validate INHBB OS association in ≥1 independent CRC cohort with available bulk RNA-seq or microarray and stromal score (ESTIMATE/MCP-counter); orthogonal check by IHC for Activin B protein.
- **Confidence label:** **Supported hypothesis** (single-cohort statistics, but with external literature mechanistic support).

### Priority 2 — NT5E (CD73) as a prognostic and immunotherapy-stratification biomarker (Biomarker + Therapeutic target)
- **Why prioritize:** Risk-associated HR 1.31 with consistent direction across probes (rows=4); CD73/adenosinergic axis has clinical-stage inhibitors (oleclumab etc., trials retrieved in supplied pack).
- **Current evidence:** HR 1.31, FDR 0.045; independent literature (PMID 36480312) supports prognostic and immunotherapy-stratification relevance across cancers.
- **External support:** ClinicalTrials.gov records (32/100) and CIViC (7/100) corroborate active clinical development. The existence of drugs does **not** prove efficacy in CRC specifically — must remain a biomarker/stratification claim.
- **Next step:** Test NT5E expression as a predictor of OS in an independent cohort stratified by ICI exposure; correlate with CD8+ T-cell infiltration and adenosine-pathway gene signatures.
- **Confidence label:** **Supported hypothesis** for prognosis; **exploratory hypothesis** for ICI response prediction.

### Priority 3 — Mitochondrial OXPHOS loss as a metabolic-risk module (Mechanistic hypothesis)
- **Why prioritize:** Most directionally coherent cluster in the entire signature (≈ 15 genes, near-uniform protective direction), with internal STRING edges (CS–ACSS2, COA3–MT-CO1).
- **Current evidence:** Uniform protective HR 0.69–0.77 across NDUFA9, OGDHL, ATP5B, ATP5G1, COA3, CS, ACSS2, PRELID2, ILVBL, etc. KEGG "Glyoxylate and dicarboxylate metabolism" enriched by the supplied RAG.
- **External support:** Consistent with the Warburg literature and with reports of Complex I loss marking aggressive CRC; however, no independent-cohort statistic is provided.
- **Next step:** Build a small "OXPHOS score" (mean z-score of NDUFA9, OGDHL, ATP5B, ATP5G1, COA3, CS, ACSS2) and test association with OS in ≥1 independent cohort; compare with MSI status and CMS subtype.
- **Confidence label:** **Supported hypothesis** at the cluster level; **exploratory** at the per-gene level.

### Priority 4 — CDX2 loss-of-expression as a clinically actionable poor-prognosis marker (Biomarker)
- **Why prioritize:** CDX2 is independently established (PMID 30631044) as a suppressor of CRC proliferation via GSK-3β/Axin2/Wnt; supplied HR 0.75 is consistent.
- **Current evidence:** HR 0.75, FDR 0.036.
- **External support:** Strong, independent of this dataset.
- **Next step:** Confirm CDX2 OS effect in an independent cohort, ideally stratified by MSI/CMS; consider CDX2 IHC (clinically available) as a low-cost validation.
- **Confidence label:** **Established evidence** for CDX2 favorable prognosis in MSS CRC; the supplied dataset adds confirmatory evidence.

### Priority 5 — LRCH1–LRCH3–DOCK6/7/8 interaction module in invasion (Interaction / network hypothesis)
- **Why prioritize:** This is the only cluster in the signature with multiple high-confidence direct physical interaction edges from STRING (LRCH1↔LRCH3↔DOCK6/7/8↔LRCH4) and both genes are risk-associated.
- **Current evidence:** LRCH1 HR 1.34, LRCH3 HR 1.34, both at FDR ~0.04–0.06.
- **External support:** Direct STRING edges = supplied interaction evidence. CRC-specific functional evidence: **insufficient evidence** in the supplied pack.
- **Next step:** Co-IP of LRCH1/LRCH3 with DOCK family members in a CRC cell line; test whether knock-down alters migration/invasion readouts.
- **Confidence label:** **Exploratory hypothesis**.

## 5. Evidence Grounding Summary

- **Direct dataset evidence (primary):** All HR/FDR/P values used to assign risk vs protective direction come from the supplied survival analysis ledger. This is the only direct statistical input.
- **Pathway / ontology evidence:** Reactome, QuickGO, and KEGG records (full coverage of 100/100 in Reactome; 79/100 in QuickGO) supply the ontology assignments used for Programs 1, 3, 4, 5. Note that Reactome and QuickGO may share underlying annotation pipelines, so they are **not fully independent** of each other.
- **Protein interaction evidence:** Direct STRING edges cited above for FGF19–KLB/FGFR4 and for the LRCH1–LRCH3–DOCK6/7/8 module. Network edges for the EMT cluster are largely **indirect** (pathway co-membership), not direct binding.
- **Disease-association evidence:** GWAS 100/100, ClinVar 83/100, OpenTargets 40/100 records exist but most do not produce per-gene replication statistics for OS in this cohort.
- **Expression/tissue evidence:** GTEx (81/100) and HPA (75/100) provide tissue-expression context; these are **contextual**, not prognostic.
- **Therapeutic evidence:** ChEMBL (14/100), CIViC (7/100), ClinicalTrials (32/100). Used only for the NT5E priority; drug existence is not interpreted as efficacy.
- **Published literature evidence:** PubMed 699 articles and Europe PMC 866 articles retrieved. Specifically used: PMID 41992239 (INHBB in CRC), PMID 36480312 (NT5E cancer prognosis), PMID 30631044 (CDX2 in colon cancer), PMID 34342374 (LINC00852 in NSCLC, not CRC), PMID 17135288 (ATP23 prohibitin genetics), PMID 42363170 (mesothelin CAR-T in CRC organoids).
- **Independent-cohort validation:** **Not available** in the supplied pack. Any claim that a program is "enriched" or "validated" should be read as supported by the input dataset + external annotation, not by an independent statistical replication.

Conflicts: BCL2L14 and DCBLD2 show probe-level direction conflicts (rows=4 each); their final HRs above are cohort-level summary rows from the supplied ledger. SCEL likewise has probe-level inconsistency. These should be interpreted at the cohort-level direction, not as individually confirmed.

## 6. Limitations and Alternative Explanations

1. **Tumor purity and stromal confounding (most important).** INHBB, FGF19, DCBLD2, and several other risk genes are highly expressed in stromal/fibroblast compartments. The OS signal may partly reflect tumor-stroma ratio rather than tumor-cell-intrinsic biology. Investigation: correlate gene expression with ESTIMATE/MCP-counter stromal scores; validate top genes by IHC in epithelial vs stromal compartments.

2. **Cell-composition and differentiation state.** The protective CDX2/CDX1/LGALS4 module may partially reflect residual differentiated epithelium rather than an active tumor-cell protective program. The same applies to the mitochondrial cluster — high OXPHOS transcripts may simply mark less dedifferentiated, less proliferative tumor cells. Investigation: stratify by tumor grade, MSI status, and CMS subtype (CMS1–4) where available.

3. **Association vs causation.** All signatures are derived from Cox regression of bulk expression vs OS. No claim here establishes causality; directional HR is association, not mechanism. The Activin/EMT/immune modules are candidate mechanisms, not proven ones.

4. **Platform, batch, and probe-level artifacts.** The signature contains 53 duplicated probes/genes and several direction-conflict probes (DCBLD2, BCL2L14, LOC101928747|RBMX|SNORD61). The supplied ledger resolves these to a single representative row per gene, but the underlying heterogeneity may indicate probe-specific artifacts (alternative splicing, cross-hybridization, or platform shifts between Affymetrix probe sets). A combined-probe reanalysis is warranted before clinical use.

5. **Small subgroup / unmeasured confounding.** Standard prognostic covariates (stage, MSI, CMS, treatment exposure, age, sex) are not provided. Stage-adjusted residual HRs are unavailable; the signatures may be partly stage proxies (e.g., CDX2 and OXPHOS loss are more common in poorly differentiated/high-stage tumors). Investigation: multivariate Cox with stage, MSI, and treatment covariates.

6. **Probe-only genes of unknown identity.** A non-trivial fraction of rows are PROBE_* identifiers without annotated gene targets; these should not be promoted to "key genes" without re-annotation.

In summary, the supplied 100-gene CRC OS signature is best understood as a coordinate readout of (i) an adverse EMT/TGF-β/Activin axis with INHBB and DCBLD2 as top individual hits, (ii) a protective intestinal-differentiation axis anchored by CDX2, and (iii) a strikingly coherent protective mitochondrial-OXPHOS metabolic module. Each of these is a **supported hypothesis**, not yet an **established prognostic factor**, because independent-cohort replication was not supplied. The most actionable near-term validation steps are independent-cohort OS validation of INHBB and the OXPHOS-score, CDX2 IHC confirmation, and NT5E stratification in ICI-treated cohorts — while explicitly controlling for tumor purity, MSI status, and stage.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=21, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
